Table 4.
Simple regression | Multiple regression | |||||
---|---|---|---|---|---|---|
Variable | Adjusted R-square | β-coeff | p value | Adjusted R-square | β-coeff | p value |
DXR decrease (mg/cm2/month)a | 0.049 | −0.235 | 0.002 | 0.069 | −0.181 | 0.033 |
DAS28b | 0.015 | 0.148 | 0.070 | 0.028 | 0.767 | |
Larsen scoreb | 0.017 | 0.153 | 0.049 | 0.068 | 0.404 | |
Ageb | 0.001 | 0.082 | 0.291 | |||
Gender | 0.007 | 0.114 | 0.143 | 0.071 | 0.381 | |
anti-CCP2 statusb | 0.010 | −0.125 | 0.107 | −0.128 | 0.114 | |
RFb | −0.001 | −0.069 | 0.385 | |||
Corticosteroid treatment | −0.002 | 0.042 | 0.417 | |||
Disease duration (months)b | −0.006 | 0.026 | 0.739 | |||
CRP (mg/L)b | −0.004 | 0.045 | 0.566 | |||
ESR (mm/h)b | 0.024 | 0.173 | 0.025 | 0.133 | 0.165 | |
DAS28 > 2.6 at 3 months | −0.002 | 0.065 | 0.422 |
Abbreviations: DXR digital X-ray radiogrammetry, DAS28 Disease Activity Score in 28 joints, CCP cyclic citrullinated peptides, RF rheumatoid factor, CRP C-reactive protein, ESR erythrocyte sedimentation rate, BMD bone mineral density
aDecrease in DXR-BMD between baseline and 3 months
bBaseline value